Rho kinase inhibitor fasudil reduces l‐DOPA‐induced dyskinesia in a rat model of Parkinson's disease
- 28 September 2020
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 177 (24) , 5622-5641
Abstract
Background and Purpose: Rho kinase (ROCK) activation is involved in neuroinflammatory processes leading to progression of neurodegenerative diseases such as Parkinson's disease. Furthermore, ROCK plays a major role in angiogenesis. Neuroinflammation and angiogenesis are mechanisms involved in developing l‐DOPA‐induced dyskinesias (LID). However, it is not known whether ROCK plays a role in LID and whether ROCK inhibitors may be useful against LID.Experimental Approach: In rats, we performed short‐ and long‐term dopaminergic lesions using 6‐hydroxydopamine and developed a LID model. Effects of dopaminergic lesions and LID on the RhoA/ROCK levels were studied by western blot, real‐time PCR analyses and ROCK activity assays in the substantia nigra and striatum. The effects of the ROCK inhibitor fasudil on LID were particularly investigated.Key Results: Short‐term 6‐hydroxydopamine lesions increased nigrostriatal RhoA/ROCK expression, apparently related to the active neuroinflammatory process. However, long‐term dopaminergic denervation (completed and stabilized lesions) led to a decrease in RhoA/ROCK levels. Rats with LID showed a significant increase of RhoA and ROCK expression. The development of LID was reduced by the ROCK inhibitor fasudil (10 and 40 mg·kg−1), without interfering with the therapeutic effect of l‐DOPA. Interestingly, treatment of 40 mg·kg−1 of fasudil also induced a significant reduction of dyskinesia in rats with previously established LID.Conclusion and Implications: The present results suggest that ROCK is involved in the pathophysiology of LID and that ROCK inhibitors such as fasudil may be a novel target for preventing or treating LID. Furthermore, previous studies have revealed neuroprotective effects of ROCK inhibitors.Keywords
Funding Information
- Consellería de Cultura, Educación e Ordenación Universitaria, Xunta de Galicia (ED431G/05, ED431C 2018/10)
- European Regional Development Fund
- Instituto de Salud Carlos III (RD16/0011/0016)
- Secretaría de Estado de Investigación, Desarrollo e Innovación (RTI2018‐098830‐B‐I00)
This publication has 60 references indexed in Scilit:
- Intravitreal Administration of HA-1077, a ROCK Inhibitor, Improves Retinal Function in a Mouse Model of Huntington DiseasePLOS ONE, 2013
- ROCK/Cdc42-mediated microglial motility and gliapse formation lead to phagocytosis of degenerating dopaminergic neurons in vivoScientific Reports, 2012
- Vascular endothelial growth factor is upregulated by l-dopa in the parkinsonian brain: implications for the development of dyskinesiaBrain, 2011
- Multiple roles for RhoA during T cell transendothelial migrationSmall GTPases, 2010
- RhoA/ROCK signaling is essential for multiple aspects of VEGF‐mediated angiogenesisThe FASEB Journal, 2010
- Maladaptive striatal plasticity in l-DOPA-induced dyskinesia2010
- Statins inhibit Rho kinase activity in patients with atherosclerosisAtherosclerosis, 2009
- Novel interactions between the 5‐HT transporter, 5‐HT1B receptors and Rho kinase in vivo and in pulmonary fibroblastsBritish Journal of Pharmacology, 2008
- Exogenous corticosterone reduces l-DOPA-induced dyskinesia in the hemi-parkinsonian rat: Role for interleukin-1βNeuroscience, 2008
- A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhageSurgical Neurology, 2007